The value of routinely combining the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators with multiparametric magnetic resonance imaging to predict clinically significant prostate cancer remains uncertain

John W. Yaxley, Robert A. Gardiner


Multiparametric magnetic resonance imaging (mpMRI) has emerged as a most useful tool for triaging patients with a suspicion of harbouring prostate cancer (PCa). mpMRI findings are ranked by the Prostate Imaging Reporting and Data System (PI-RADS) which has been refined into the current PI-RADs 2 version, this topic having been reviewed recently by Roberts et al. in 2018 (1). mpMRI also has the ability to localise non-palpable cancer within the prostate, which if performed before a prostate biopsy will increase the diagnosis of significant PCa (2-4).